These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 26992254)
1. Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Malignant and Benign Biliary Obstructions. Abdel-Razik A; ElMahdy Y; Hanafy EE; Elhelaly R; Elzehery R; M Tawfik A; Eldars W Am J Med Sci; 2016 Mar; 351(3):259-64. PubMed ID: 26992254 [TBL] [Abstract][Full Text] [Related]
2. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Alvaro D; Macarri G; Mancino MG; Marzioni M; Bragazzi M; Onori P; Corradini SG; Invernizzi P; Franchitto A; Attili AF; Gaudio E; Benedetti A Ann Intern Med; 2007 Oct; 147(7):451-9. PubMed ID: 17909206 [TBL] [Abstract][Full Text] [Related]
3. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions. Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676 [TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor levels in bile distinguishes pancreatic cancer from other etiologies of biliary stricture: a pilot study. Navaneethan U; Gutierrez NG; Jegadeesan R; Venkatesh PG; Poptic E; Liu X; Sanaka MR; Jang S; Vargo JJ; Parsi MA Dig Dis Sci; 2013 Oct; 58(10):2986-92. PubMed ID: 23828141 [TBL] [Abstract][Full Text] [Related]
5. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin. Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978 [TBL] [Abstract][Full Text] [Related]
6. Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses. Farina A; Dumonceau JM; Antinori P; Annessi-Ramseyer I; Frossard JL; Hochstrasser DF; Delhaye M; Lescuyer P Biochim Biophys Acta; 2014 May; 1844(5):1018-25. PubMed ID: 23806607 [TBL] [Abstract][Full Text] [Related]
7. High Bile Titer and High Bile to Serum Ratio of CYFRA 21 - 1 Reliably Discriminate Malignant Biliary Obstruction Caused by Cholangiocarcinoma. Chen J; Liang J; Xu B; Liang J; Ma M; Wang Z; Zeng G; Xu Q; Liang L; Lai J; Huang L J Gastrointest Cancer; 2024 Jun; 55(2):800-808. PubMed ID: 38280173 [TBL] [Abstract][Full Text] [Related]
8. Serum and bile biomarkers for cholangiocarcinoma. Alvaro D Curr Opin Gastroenterol; 2009 May; 25(3):279-84. PubMed ID: 19396965 [TBL] [Abstract][Full Text] [Related]
9. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. Bertram S; Padden J; Kälsch J; Ahrens M; Pott L; Canbay A; Weber F; Fingas C; Hoffmann AC; Vietor A; Schlaak JF; Eisenacher M; Reis H; Sitek B; Baba HA J Clin Pathol; 2016 Jul; 69(7):619-26. PubMed ID: 26729014 [TBL] [Abstract][Full Text] [Related]
10. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699 [TBL] [Abstract][Full Text] [Related]
11. The value of biliary fibronectin for diagnosis of cholangiocarcinoma. Chen CY; Lin XZ; Tsao HC; Shiesh SC Hepatogastroenterology; 2003; 50(52):924-7. PubMed ID: 12845951 [TBL] [Abstract][Full Text] [Related]
12. C-reactive protein and insulin-like growth factor-1 in differential diagnosis of ascites. Abdel-Razik A; Eldars W; Elhelaly R; Elzehery R J Gastroenterol Hepatol; 2016 Nov; 31(11):1868-1873. PubMed ID: 27010362 [TBL] [Abstract][Full Text] [Related]
14. An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis. Lukic N; Visentin R; Delhaye M; Frossard JL; Lescuyer P; Dumonceau JM; Farina A Biochim Biophys Acta; 2014 May; 1844(5):1026-33. PubMed ID: 23872482 [TBL] [Abstract][Full Text] [Related]
15. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study. Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272 [TBL] [Abstract][Full Text] [Related]
16. Can red cell distribution width help to discriminate benign from malignant biliary obstruction? A retrospective single center analysis. Beyazit Y; Kekilli M; Ibis M; Kurt M; Sayilir A; Onal IK; Purnak T; Oztas E; Tas A; Yesil Y; Arhan M Hepatogastroenterology; 2012; 59(117):1469-73. PubMed ID: 22683963 [TBL] [Abstract][Full Text] [Related]
18. The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma. Rose JB; Correa-Gallego C; Li Y; Nelson J; Alseidi A; Helton WS; Allen PJ; D'Angelica MI; DeMatteo RP; Fong Y; Kingham TP; Kowdley KV; Jarnagin WR; Rocha FG PLoS One; 2016; 11(3):e0150195. PubMed ID: 26974538 [TBL] [Abstract][Full Text] [Related]
19. Bile duct: analysis of percutaneous transluminal forceps biopsy in 130 patients suspected of having malignant biliary obstruction. Jung GS; Huh JD; Lee SU; Han BH; Chang HK; Cho YD Radiology; 2002 Sep; 224(3):725-30. PubMed ID: 12202706 [TBL] [Abstract][Full Text] [Related]
20. Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring. Wen N; Peng D; Xiong X; Liu G; Nie G; Wang Y; Xu J; Wang S; Yang S; Tian Y; Li B; Lu J; Cheng N Signal Transduct Target Ther; 2024 May; 9(1):107. PubMed ID: 38697972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]